Clinical trials: Thorough QT/QTc Study
Healthy Volunteers
ADASUVE 2-dose Thorough QT/QTc Study
Assess the potential effects on the QT interval of 2 consecutive doses of ADASUVE administered 2 hours apart, in relation to placebo and an active control in healthy volunteers.
- Trial name
- NCT01854710
- Testing
- ADASUVE 10 mg 2 doses 2 hours apart, Oral moxifloxacin 400 mg
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.
Healthy
T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers
This dedicated T/QT study will investigate the effect of relacorilant on cardiac repolarization in healthy participants.
- Trial name
- NCT04795479
- Testing
- Relacorilant, Moxifloxacin
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Healthy Volunteers
A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants
The purpose of this study is to evaluate the effect of BMS-986278 on the cardiac repolarization in healthy participants.
- Trial name
- NCT07422298
- Testing
- BMS-986278, Moxifloxacin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers
This is a single-center, multiple-dose, randomized, double-blind, double-dummy, placebo-controlled, active-comparator, parallel study in healthy volunteers.
- Trial name
- NCT01689116
- Testing
- Bardoxolone Methyl 20mg, Bardoxolone Methyl 80mg, Moxifloxacin 400mg
- Where
- United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Biogen
Contraception
Thorough QT/QTc Study of Multiple Oral Doses of NOMAC-E2 (Org 10486 0 + Org 2317) in Healthy Women (Study 292011)(P05802)
The trial is a single-center randomized, double-blind, double-dummy, placebo and positive controlled, parallel group clinical trial.
- Trial name
- NCT00779532
- Testing
- Moxifloxacin, NOMAC-E2 (Org 10486-0 + Org 2317)
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Human Experimentation (Human Volunteers)
Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers
This phase I trial will evaluate the effects of rupatadine, at a dose of 10 mg OD (authorised and marketed dose) and the 100mg/day (supratherapeutic dose) on the ECG parameters with a special focus on its effect on cardiac…
- Trial name
- NCT00199225
- Testing
- Rupatadine, moxifloxacin, Continous electrocardiographic register
- Where
- Spain
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- J. Uriach and Company
Healthy Volunteers
A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of BMS-986419 (Part 1) and the effects of multiple doses of BMS-986419 on cardiac repolarization (Part 2) in healthy participants.
- Trial name
- NCT06846866
- Testing
- BMS-986419, Moxifloxacin
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy
A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)
The purpose of this study is to assess the effects on placebo-corrected change from baseline QT interval corrected for individual heart rate (QTcI) of JNJ-64565111 close to steady state on Day 26 and on electrocardiogram…
- Trial name
- NCT03606057
- Testing
- JNJ-64565111, Moxifloxacin
- Where
- United States
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Smoking Cessation
Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers
The primary objective of this trial is to assess the effects of cytisinicline at therapeutic and supratherapeutic doses on cardiac repolarization relative to placebo in healthy adult subjects who are smokers.
- Trial name
- NCT05566288
- Testing
- Cytisinicline, Moxifloxacin
- Where
- Portugal
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Achieve Life Sciences
Hyperuricemia, Gout
Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects
This is a Phase 1, single-center, randomized, partially double-blind, placebo- and positive controlled, 4-way crossover study to evaluate the effect of a therapeutic and a supratherapeutic dose of LC350189 on the QTcF in healthy…
- Conditions
- Hyperuricemia, Gout, Qt Interval, Variation in
- Trial name
- NCT04966325
- Testing
- LC350189 200mg, Moxifloxacin 400mg, LC350189 600mg
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- LG Chem
Healthy Subject
Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
This is A Randomized, Blinded, Placebo- and Positive-Controlled, Four-Period, Crossover-Design Thorough QT/QTc (TQT) Study to Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects
- Trial name
- NCT05660720
- Testing
- Orelabrutinib, Moxifloxacin hydrochloride
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Healthy Volunteers
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of high dose of BMS-986278 in healthy participants and to assess the effect of BMS-986278 on the ECG intervals in healthy participants.
- Trial name
- NCT06746402
- Testing
- BMS-986278, Moxifloxacin
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Cough, Endometriosis
Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants
In this study, researchers want to find whether the study drug BAY1817080 has an effect on the electrocardiogram (ECG). 40 healthy male or female participants with the age of 18 to 65 years will be enrolled into this study.
- Conditions
- Cough, Endometriosis, Overactive Bladder
- Trial name
- NCT04423744
- Testing
- BAY1817080, Moxifloxacin
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Bayer
Torsades de Pointes
A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers
Determine whether VI-0521 has an effect on the electrical activity of the heart in healthy subjects. Find out how much VI-0521 is in the blood and any potential side effects on ECG's of healthy subjects after taking the study…
- Trial name
- TQT (NCT00839891)
- Testing
- VI-0521
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Pain
A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants
The purpose of the study is to evaluate the effects of clinical and high clinical exposures of VX-548 and its metabolite on QTcF, and the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VX-548 and its…
- Trial name
- NCT05818852
- Testing
- VX-548, Moxifloxacin
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
TTR Cardiomyopathy
A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)
The purpose of this study is to investigate the effects of tafamidis on the intervals of the electrocardiogram, specifically the rate corrected QT interval (QTc) in healthy volunteers.
- Trial name
- NCT01775761
- Testing
- Period 1, Period 2, Period 3
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects
Thorough QT/QTc of Pritelivir in Healthy Subjects
This Phase 1 clinical trial was a double-blind, single-center, randomized and placebo-controlled trial in which healthy male and female subjects received in 2 parallel-groups daily oral doses of pritelivir (Group 1) or matching…
- Trial name
- NCT05671029
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AiCuris Anti-infective Cures AG
Cardiac Effects in Normal Healthy Volunteers
A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers
The purpose of this study is to determine if the study drug, ACHN-490 Injection, affects the QT interval in normal volunteers. The hypothesis is that the drug will not cause an increase in the QT interval.
- Trial name
- NCT01514929
- Testing
- ACHN-490 Injection, Moxifloxacin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Achaogen, Inc.
Healthy
A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm
The purpose of this study is to assess whether multiple doses of Talampanel increase the QT interval when compared to placebo
- Trial name
- NCT00964730
- Testing
- Talampanel, Moxifloxacin
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Healthy
A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as the active control.
- Trial name
- NCT04560816
- Testing
- ALXN1840, Moxifloxacin
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.